Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)

Exclusion Criteria

• •Acute promyelocytic leukemia (APL)
• •Previous or concurrent malignancies other than AML
• •Previous treatment with colony-stimulating factors, interleukins or interferons
• •Known hypersensitivity to Escherichia coli derived products (e.g. Filgrastim, HUMULIN® Insulin, L-Asparaginase, HUMATROPE® Growth Hormone, INTRON A®)
• •Antibody-based or cell-based immunotherapies
• •Respiratory insufficiency with pO2 \<60 mmHg
• •Heart failure NYHA III° or IV°
• •Elevated creatinine \>2.0 mg/dl
• •Elevated bilirubin \>2.0 mg/dl
• •Pregnancy or lactation
• •Females without adequate contraception
• •Known HIV and/or hepatitis C infection
• •Severe neurologic or psychiatric disease
• •Psychiatric, addictive, or any disorder, which compromises ability to give truly informed consent for participation in this study
• •Concerns for subject's compliance with the protocol procedures
• •Lack of willingness to record and circulate personal disease-related informations defined in the study protocol